New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]
Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E, Pajno GB, Incorvaia C. Biologics: Targets and Therapy. 2014;8:221–226.On page 223, Figure 1 should be replaced with the revised version as shown below:On page 224, line 4 in the left column, "many&a...
Enregistré dans:
| Auteurs principaux: | Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno GB, Incorvaia C |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2015
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e08611437a334897a46acc787d6961de |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
par: Frati F, et autres
Publié: (2014) -
Sublingual immunotherapy increases Treg/Th17 ratio in allergic rhinitis
par: Wang Jiarong, et autres
Publié: (2021) -
Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis
par: Galateja Jordakieva, et autres
Publié: (2017) -
Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
par: Tankersley M, et autres
Publié: (2021) -
Seasonal changes in nasal cytology in mite-allergic patients
par: Gelardi M, et autres
Publié: (2014)